We are live on ! Find out more

CAMP4 Therapeutics

CAMP

Market cap $255M

4.06 USD

+0.34

9.14%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

4.22

+0.16

3.94%

1 day

9.14%

5 days

1%

1 month

2.53%

3 months

-9.78%

6 months

0%

Year to date

-32.33%

1 year

-8.76%

5 years

-62.13%

10 years

-62.13%

About: Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.

Employees: 48

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.7%

Neutral 69.2%

Negative 23.1%

Zacks Investment Research

CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.55 per share a year ago.

CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates

CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina Company remains on track to dose first patient by year-end 2026 Hosted Virtual Analyst Day highlighting the unmet need in SYNGAP1-related disorder and the design of the ASCEND Phase 1/2 clinical; announced SHANK3 for Phelan-McDermid syndrome as next pipeline program Received $50.1 million from second closing of private placement; cash and cash equivalents of $124.5 million as of September 30, 2026, with cash runway expected through the end of 2028 WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the third quarter ended September 30, 2026, and provided recent corporate highlights.

CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights

Zacks Investment Research

CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease

Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length proteins.

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease

CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference

WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan's 10th Annual Healthcare Conference on October 20, 2026. Details below:

CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028.

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4's executive leadership team and participation from patient advocates and a leading KOL. To register, click here.

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

See News Rankings

Price charts implemented using Lightweight Charts™